Blog Category
News
December
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine i...
December 3rd, 2018
LUGANO, Switzerland and San Diego, USA, December 3, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products...
Read articleHelsinn and Mundipharma China Pharmaceutical announce tha approval of ALOXI®IV b...
December 3rd, 2018
Approval by the National Medical Products Administration (NMPA) brings ALOXI® to a large new patient population ALOXI® is a globally approved anti-em...
Read articleNovember
Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innov...
November 27th, 2018
The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their idea to the market for cancer p...
Read articleONO Submits an Application for Manufacturing and Marketing Approval of Anamoreli...
November 27th, 2018
Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President and Representative Director: Gyo Sagara; “ONO”) announced today that ONO has submitted in Japan ...
Read articleOctober
September
Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting
September 26th, 2018
Read articleAugust
July
June
Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual...
June 26th, 2018
Leading cancer supportive care experts in oncology explore how to provide the best care for patients by discussing the importance of improving adheren...
Read articleSecond Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (...
June 4th, 2018
Lugano, Switzerland, June 4, 2018 –Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, in conjunction with the C...
Read articleMay
April
NovellusDx announces it has completed an equity financing of $6 million
April 30th, 2018
NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the par...
Read articleHelsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Ann...
April 24th, 2018
Poster: Budget Impact of Fixed Combination NEPA for the Prevention of Chemotherapy Induced Nausea and Vomiting
Read articleHelsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agr...
April 4th, 2018
AKYNZEO®, containing netupitant 300mg and palonosetron 0.5mg, is used for prevention of chemotherapy-induced nausea and vomiting (CINV) The licensing ...
Read articleMarch
Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology...
March 28th, 2018
Lorenzo Pradella of GreenBone Ortho, srl has been selected from eleven finalists as the winner of the first ever Lyfebulb-Helsinn Innovation Award in ...
Read articleHelsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership...
March 26th, 2018
For the fourth year running, Helsinn Advanced Synthesis has won first place in all core award categories at the 2018 CMO Leadership Awards; Quality, R...
Read articleHelsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledag...
March 21st, 2018
- Product is approved by the U.S. Food & Drug Administration and the European Commission and launched in the U.S. with global sales of $35 million i...
Read articleHelsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs N...
March 20th, 2018
Lugano, Switzerland, March 20, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announced that the...
Read articleOn Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners,...
March 14th, 2018
WEST LAFAYETTE, Ind. Mar. 14, 2018 – On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescen...
Read articleEleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation...
March 1st, 2018
Eleven finalists have been selected from a strong roster of talent to compete at the inaugural Lyfebulb-Helsinn Innovation Summit, March 26-27, Monac...
Read articleFebruary
Helsinn Files Petition for Writ of Certiorari for Supreme Court Review Regarding...
February 28th, 2018
Lugano, Switzerland,and Woodcliff Lake, N.J., February 28, 2018 – In response to the United States Court of Appeals for the Federal Circuit holding c...
Read articleHelsinn Group announces the appointment of Paul Rittman as Chief Executive Offic...
February 27th, 2018
Helsinn, a Swiss pharmaceutical group focused on building quality cancercare products, today announces that Paul Rittman has been appointed as ChiefEx...
Read articleJanuary
Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement
January 30th, 2018
Investigating the role of pharmacological inhibitors in kidney cancer
Read articleHelsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug ...
January 11th, 2018
Lugano, Switzerland, and San Diego, USA, January 11, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, an...
Read articleA call for action to patient entrepreneurs in the area of cancer to compete at t...
January 9th, 2018
The Award recognizes Patient Entrepreneurs’ Innovative Efforts and Ideas for cancer and cancer supportive care using drugs, medical devices, consumer ...
Read articleHelsinn to honor Anna Braglia Endowed Young Investigator Award recipient at Hels...
January 8th, 2018
Dr. Sarah A. Buckley to be recognized as the inaugural Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care recipient during the JP...
Read article